Glioblastomas (GBMs) are very aggressive and almost incurable brain tumors. The development of new therapeutical approaches capable of selectively killing cancer cells could represent a step forward to fight cancer. With this aim we tested the efficacy of a novel oncolytic therapy based on recombinant herpes simplex viruses (HSVs) infecting exclusively cells expressing the human receptor HER-2 [1, 2], overexpressed in about 15% of GBMs [3]. For this study we exploited a murine GBM model based on PDGF-B embryonic transduction [4, 5]. We engineered cell cultures derived from this model to express HER-2 and we injected intracranically such cultures in NOD/SCID mice. We evaluated the efficacy of R-LM113, a recombinant HSV directed to HER-2, in this glioma model expressing HER-2. We demonstrated that mice injected with engineered glioma cells infected with R-LM113 developed gliomas with a statistically significant delay compared to mice injected with non-infected engineered glioma cells.

A murine model for virotherapy of malignant brain tumors.

MENOTTI, LAURA;
2011

Abstract

Glioblastomas (GBMs) are very aggressive and almost incurable brain tumors. The development of new therapeutical approaches capable of selectively killing cancer cells could represent a step forward to fight cancer. With this aim we tested the efficacy of a novel oncolytic therapy based on recombinant herpes simplex viruses (HSVs) infecting exclusively cells expressing the human receptor HER-2 [1, 2], overexpressed in about 15% of GBMs [3]. For this study we exploited a murine GBM model based on PDGF-B embryonic transduction [4, 5]. We engineered cell cultures derived from this model to express HER-2 and we injected intracranically such cultures in NOD/SCID mice. We evaluated the efficacy of R-LM113, a recombinant HSV directed to HER-2, in this glioma model expressing HER-2. We demonstrated that mice injected with engineered glioma cells infected with R-LM113 developed gliomas with a statistically significant delay compared to mice injected with non-infected engineered glioma cells.
2011
Gambini E.; Reisoli E.; Appolloni I.; Menotti L.; Malatesta P.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/122010
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact